Your browser doesn't support javascript.
loading
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project.
Shaaban, Abeer M; Hilton, Bridget; Clements, Karen; Dodwell, David; Sharma, Nisha; Kirwan, Cliona; Sawyer, Elinor; Maxwell, Anthony; Wallis, Matthew; Stobart, Hilary; Mylvaganam, Senthurun; Litherland, Janet; Brace-McDonnell, Samantha; Dulson-Cox, Joanne; Kearins, Olive; Provenzano, Elena; Ellis, Ian O; Pinder, Sarah E; Thompson, Alastair M.
Afiliação
  • Shaaban AM; Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK. a.shaaban@bham.ac.uk.
  • Hilton B; NHS England and NHS Improvement, Birmingham, UK.
  • Clements K; NHS England and NHS Improvement, Birmingham, UK.
  • Dodwell D; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Sharma N; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Kirwan C; Division of Informatics, Imaging & Data Sciences. School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK.
  • Sawyer E; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Comprehensive Cancer Centre at Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK.
  • Maxwell A; Division of Informatics, Imaging & Data Sciences. School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK.
  • Wallis M; Addenbrookes Hospital, Cambridge and Cambridge Breast Unit, and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK.
  • Stobart H; Independent Cancer Patients' Voice, London, UK.
  • Mylvaganam S; Royal Wolverhampton Hospital NHS Trust, Wolverhampton, UK.
  • Litherland J; NHS Greater Glasgow and Clyde, Glasgow, UK.
  • Brace-McDonnell S; Independent Cancer Patients' Voice, London, UK.
  • Dulson-Cox J; NHS England and NHS Improvement, Birmingham, UK.
  • Kearins O; NHS England and NHS Improvement, Birmingham, UK.
  • Provenzano E; Addenbrookes Hospital, Cambridge and Cambridge Breast Unit, and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK.
  • Ellis IO; Nottingham University Hospitals, Nottingham, UK.
  • Pinder SE; Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK.
  • Thompson AM; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Comprehensive Cancer Centre at Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK.
Br J Cancer ; 127(12): 2125-2132, 2022 12.
Article em En | MEDLINE | ID: mdl-36224403
ABSTRACT

BACKGROUND:

The diagnosis, management and prognosis of microinvasive breast carcinoma remain controversial.

METHODS:

We analysed the outcomes of patients with DCIS with and without microinvasion diagnosed between 2003 and 2012 within the Sloane project.

RESULTS:

Microinvasion was recorded in 521 of 11,285 patients (4.6%), with considerable variation in reported incidence among screening units (0-25%). Microinvasion was associated with high-grade DCIS, larger DCIS size, comedo necrosis and solid, cribriform architecture (all P < 0.001). Microinvasion was more frequent in patients who underwent mastectomy compared with breast-conserving surgery (BCS) (6.9% vs 3.6%, P < 0.001), and in those undergoing axillary nodal surgery (60.4% vs 30.3%, P < 0.001) including the subset undergoing BCS (43.4% vs 8.5%, P < 0.001). Nodal metastasis rate was low and not statistically significant difference from the DCIS only group (P = 0.68). Following median follow-up of 110 months, 3% of patients had recurrent ipsilateral high-grade DCIS, and 4.2% developed invasive carcinoma. The subsequent ipsilateral invasion was of Grade 3 in 71.4% of patients with microinvasion vs 30.4% in DCIS without microinvasion (P = 0.02). Distant metastasis and breast cancer mortality were higher with microinvasion compared with DCIS only (1.2% vs 0.3%, P = 0.01 and 2.1% vs 0.8%; P = 0.005).

CONCLUSIONS:

The higher breast cancer mortality with microinvasion indicates a more aggressive disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Limite: Female / Humans País/Região como assunto: Europa Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Limite: Female / Humans País/Região como assunto: Europa Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido